Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2015 May 6;14(7):1680–1692. doi: 10.1158/1535-7163.MCT-15-0080

Figure 2.

Figure 2

Vemurafenib causes a decrease in glucose uptake in drug-sensitive but not resistant lines. A, Treatment with 3μM Vemurafenib causes a decrease in glucose uptake as assessed by flow cytometry using the fluorescent glucose analog 2-NBDG reaching maximum decrease by 72 hours. B, Acquired-resistant lines (e.g. YUMACr) that have been serially passaged in 5μM Vemurafenib show a much lower decrease in glucose uptake than drug-naive lines (e.g. YUMACs). C, Changes in glucose uptake with BRAF inhibition mirror resistance status and are genotype-specific. D, Glucose uptake loss due to vemurafenib treatment is reversible. All cells were incubated in 3μM vemurafenib or DMSO vehicle for 72 hours. After 72 hours, the pulse-chase group had vemurafenib-supplemented media aspirated, was washed with PBS, and re-supplied with normal media supplemented with vehicle.